Technology

WHO resumes research on hydroxychloroquine as new corona therapy


Note

WHO resumes research on hydroxychloroquine as new corona therapy

As a remedy for a novel coronavirus infectious disease (COVID-19) by the World Health Organization (WHO), which was suspended because of "the risk of death and heart disease is increased when taken."HydroxychloroquineResearch will be resumed.

WHO Director-General's opening remarks at the media briefing on COVID-19-03 June 2020
https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—03-june-2020


WHO resumes coronavirus trial on hydroxychloroquine after examining safety issues
https://www.cnbc.com/2020/06/03/world-health-organization-resumes-coronavirus-trial-on-malaria-drug-hydroxychloroquine-after-safety-concerns.html

WHO resumes hydroxychloroquine study for Covid-19
https://www.statnews.com/2020/06/03/who-resuming-hydroxychloroquine-study-for-covid-19/

Hydroxychloroquine has been used as an antimalarial drug, and has been attracting attention as a therapeutic drug for new coronavirus infections. However, due to side effectsSignificant increase in risk of death and heart complicationsMay 25, 2020 (Monday) WHOSuspended research on hydroxychloroquineThen announced.

WHO suspends research on “hydroxychloroquine'', which was expected as a new corona treatment-GIGAZINE

The study suspension was designed to assess the potential benefits and risks of hydroxychloroquine, and was discontinued in a comment from WHO Executive Secretary Tedros Adamanom published Wednesday, June 3, 2020. Reopening became clear. "The data security monitoring committee reviewed the data and, based on the available data, recommended that the members of the committee have no reason to change the trial." Continues to carefully monitor the safety of all therapeutic agents in the trial."

In addition, Secretary General Tedros said he plans to test hydroxychloroquine in a study of more than 3,500 patients in 35 countries.

Copy the title and URL of this article

Source link

Do you like this article??

Show More

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button